Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.47 |
| ▸ | PDE2A | O00408 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095656 | 1.00 | PDE10A (0.47) | PDE10APDE2AKMT2APDE8BKDM4E | |
| SCHEMBL4698941 | 0.93 | PDE2A (0.42) | PDE10APDE2ACHRM3PDE4APDE4B | |
| SCHEMBL31391497 | 0.83 | PDE2A (0.46) | PDE10APDE2AKMT2APDE8BALDH1A1 | |
| SCHEMBL25746321 | 0.83 | PDE2A (0.46) | PDE10APDE2AKMT2APDE8BALDH1A1 | |
| SCHEMBL29174759 | 0.83 | PDE10A (0.43) | PDE10APDE2A | |
| SCHEMBL30095840 | 0.82 | PDE2A (0.46) | PDE2AKMT2APDE8BKDM4EALDH1A1 | |
| SCHEMBL29174903 | 0.82 | PDE2A (0.46) | PDE2AKMT2APDE8BKDM4EALDH1A1 | |
| SCHEMBL25875863 | 0.80 | PDE2A (0.41) | PDE10APDE2AALDH1A1GAAPDE4A | |
| SCHEMBL30095904 | 0.80 | PDE10A (0.43) | PDE10APDE8B | |
| SCHEMBL29174904 | 0.80 | PDE10A (0.43) | PDE10APDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-15 | — | — | US | disclosed |
| CN-117529315-A | Imidazole-containing ALK2 kinase inhibitors | 生物水晶制药公司 | 2024-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PDE10A 822/4885PDE2A 370/4885KMT2A 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.